Bristol-Myers Squibb (Belgium)
Parent institution Bristol-Myers Squibb (United States)
ROR: Yes
Works count: 408
Citations count: 32,790
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
2015 · Robert J. Motzer, Bernard Escudier, et al. · New England Journal of Medicine
Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
2011 · Caroline Robert, L. Thomas, et al. · New England Journal of Medicine
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
2014 · Stephen M. Ansell, Alexander M. Lesokhin, et al. · New England Journal of Medicine